banner
You are not using a standards compliant browser. Because of this you may notice minor glitches in the rendering of this page. Please upgrade to a compliant browser for optimal viewing:
Firefox
Internet Explorer 7
Safari (Mac and PC)
Press Release
An epigenetic difference in twins explains different risk of breast cancer
Thursday, October 18, 2012


(Image: Rodolfo Clix/STOCK.XCHNG)

Monozygotic twins have the same genome, that is, the same DNA molecule in both siblings. Despite being genetically identical, both twins may have different diseases at different times. This phenomenon is called "twin discordance". But how can people who have the same genetic sequence present different pathologies and at different ages? The explanation partly lies in the fact that the chemical signals added in the DNA to "switch off" or "switch on" genes can be different. These signals are known as epigenetic marks.

The research team led by Manel Esteller, director of the Cancer Epigenetics and Biology Program at the Bellvitge Biomedical Research Institute (IDIBELL), Professor of Genetics at the University of Barcelona and ICREA researcher, has identified an epigenetic change in the twin who will develop breast cancer but not in her healthy one. The finding has been advanced this week in the journal Carcinogenesis.

The research group led by Dr. Esteller studied the levels of DNA methylation (the best known epigenetic mark) in the blood of 36 pairs of twins diagnosed with breast cancer or healthy. Researchers analyzed half a million pieces of the genome in each twin and compared them with each other, and they found that women who have developed breast tumours showed a pathological gain of methylation in the DOK7 gene. " an epigenetic alteration associated with an increased risk of breast cancer can be detected in the sick twin a few years before the clinical diagnosis", said Dr. Esteller about the research results.

The next step for the researchers will be knowing the exact function of the DOK7 gene. "We believe it is a regulator of tyrosine kinases, an antitumor drug target already used for the treatment of breast cancer. If DOK7 performs this function, new studies to test drugs with tumour chemopreventive effects in breast cancer could be planned in the future", concludes the research coordinator.

###

Heyn H, Carmona FJ, Gomez A, Ferreira HJ, Bell JT, Sayols S, Ward K, Stefansson OA, Moran S, Sandoval J, Eyfjord JE, Spector TD, Esteller M. DNA methylation profiling in breast cancer discordant identical twins identifies DOK7 as novel epigenetic biomarker. Carcinogenesis. Published online October 10 2012.

IDIBELL-Bellvitge Biomedical Research Institute: http://www.idibell.cat



Thanks to IDIBELL-Bellvitge Biomedical Research Institute for this article.

This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.



This press release has been viewed 76 time(s).

Comments
No comments recorded.
Add Comment?

For youtube videos, paste embed code directly in the text box

-

Members do not need to provide an address

-
Rate Article
Total votes: 0
Select Comment Validation Method
Member
Name/URL (Guest)
FaceBook (Guest)
Member Commenting:


Authenticate with Facebook before submitting

OR


Make your LabSpaces comments count. Start earning LabSpaces points by becoming a member! Learn more.
Please verify that you are human: Register for LabSpaces
Make your LabSpaces comments count. Start earning LabSpaces points by becoming a member! Learn more.


Please authenticate before trying to post a comment.

If you would like to remain anonymous, please enter a new name and link below


Friends